Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

The CSL Research Acceleration Initiative (RAI)

The CSL Research Acceleration Initiative (RAI) offers funding of up to $400k USD over two years, which can contribute towards salary costs, consumables,

 

 

Application timeline and process:

  • Applicants are required to submit a 300-word non-confidential abstract via the CSL online application portal.
  • Application deadline: 20 February 2025.
  • Please contact Florian Groelly, Business Partnerships Office,  florian.groelly@medsci.ox.ac.uk to obtain the link to the online application portal.

 

Areas of interest

The CSL RAI aims to fast-track discovery of innovative biotherapies through partnerships between CSL and academics. The call is targeted at early-stage, well-defined translational proposals that align with the CSL Therapeutic and Focus Areas (see the full list in the flyer).

1. Immunology, transplant and auto-immune

2. Haematology

3. Cardiovascular

4. Renal

5. Vaccines

6. Genetic medicine

7. Plasma proteins

 

Importantly, eligible projects must be amenable to a CSL platform:

  • Plasma Protein Technology
  • Recombinant Protein Technology
  • Genetic Medicine
  • Vaccines Technology

 

Example of projects

  • Human target validation and translational studies using patient samples
  • Mechanism of action studies for therapeutic candidates
  • Benchmarking to provide proof-of-concept for the differentiation of novel therapeutics to standard-of- care or competing therapeutics in development
  • Target validation using genetic knock-out/knock-in or tool compounds in preclinical disease models
  • Characterisation of therapeutic candidates (e.g. affinity, potency, selectivity, and developability)

Contact

Please reach out to Florian Groelly at florian.groelly@medsci.ox.ac.uk if you have additional questions or wish to apply.

 

Webinars

CSL is running information webinars for academics. Please register here. 

  • Tuesday, 21 January 2025, 3pm-4pm GMT
  • Wednesday, 5 February 2025, 10am-11am GMT